U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C34H38N4O6.ClH.H2O
Molecular Weight 653.165
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEMATOPORPHYRIN HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.CC(O)C1=C(C)C2=CC3=C(C(C)O)C(C)=C(N3)C=C4N=C(C=C5NC(=CC1=N2)C(C)=C5CCC(O)=O)C(CCC(O)=O)=C4C

InChI

InChIKey=DJUQXKVMJTWUCD-UDHHKLSBSA-N
InChI=1S/C34H38N4O6.ClH.H2O/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27;;/h11-14,19-20,36-37,39-40H,7-10H2,1-6H3,(H,41,42)(H,43,44);1H;1H2/b23-11-,24-12-,25-11-,26-13-,27-14-,28-14-,29-12-,30-13-;;

HIDE SMILES / InChI
Hematoporphyrin (Photodyn), a porphyrin prepared from hemin, is used as a photosensitizer in photodynamic therapy. Photodynamic therapy is based on the use of light-sensitive photosensitizers. Photoactivation causes the formation of singlet oxygen, which produces peroxidative reactions that can cause cell damage and death. Hematoporphyrin was used as the therapeutic agent in patients with manic-depressive reactions and in patients with involutional melancholia. One of the last studies has shown, that Hematoporphyrin-Photodynamic therapy (PDT) combined with stent placement is an effective and safe treatment for extrahepatic cholangiocarcinoma (EHCC).

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Sources: DOI: 10.1176/ajp.90.6.1157
Primary
Unknown

Approved Use

Unknown
Sources: DOI: 10.1176/ajp.90.6.1157
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The use of hematoporphyrin derivative (HpD) in the localization and treatment of transitional cell carcinoma (TCC) of the bladder.
1984
Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts.
2002 Jan
Patents

Sample Use Guides

Twenty-three patients with manic-depressive reactions were treated during the depressed phase with intramuscular and oral administration of hematoporphyrin hydrochloride for an average period of 50 to 6o days. Of this number five showed marked sustained improvement, six showed moderate sustained improvement, and six were generally benefited but the course of the psychosis did not seem to be positively affected. Six gave no favorable response. Seventeen patients of 23 can be said to have been definitely helped by the treatment
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
HEMATOPORPHYRIN HYDROCHLORIDE MONOHYDRATE
MI  
Common Name English
21H,23H-PORPHINE-2,18-DIPROPANOIC ACID, 7,12-BIS(1-HYDROXYETHYL)-3,8,13,17-TETRAMETHYL-, MONOHYDROCHLORIDE, MONOHYDRATE
Common Name English
HEMATOPORPHYRIN HYDROCHLORIDE MONOHYDRATE [MI]
Common Name English
Code System Code Type Description
FDA UNII
63BCJ5R11D
Created by admin on Sat Dec 16 10:48:41 GMT 2023 , Edited by admin on Sat Dec 16 10:48:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID10362202
Created by admin on Sat Dec 16 10:48:41 GMT 2023 , Edited by admin on Sat Dec 16 10:48:41 GMT 2023
PRIMARY
CAS
6033-08-5
Created by admin on Sat Dec 16 10:48:41 GMT 2023 , Edited by admin on Sat Dec 16 10:48:41 GMT 2023
PRIMARY
MERCK INDEX
m5941
Created by admin on Sat Dec 16 10:48:41 GMT 2023 , Edited by admin on Sat Dec 16 10:48:41 GMT 2023
PRIMARY Merck Index